BioSpace News Archive

The global precision medicine market size is predicted to hit around US$ 140.69 billion by 2028 from valued at US$ 66.1 billion in 2021, growing at a CAGR of 11.5% over the forecast period 2021 to 2030.

Bioretec Ltd has published its 2021 Annual Report, Financial Statements and Report by the Board of Directors.

Photocure ASA, The Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals has obtained approval to conduct a real-world evidence study for Hexvix® in Hainan, China, in addition to the Phase III study approved last month.

Cellectis, a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced that management will participate in the Oppenheimer & Co. Annual Healthcare Conference, taking place March 15-17, 2022 as well as the Barclays Global Healthcare Conference, taking place March 15-17.

Jaguar Health, Inc. provided company updates and reported consolidated financial results for the year ended December 31, 2021.

ERYTECH Pharma,a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, provided a business update and an update on its cash position at the end of December 2021.

Myriad Genetics, Inc., a leader in genetic testing and precision medicine, announced the U.S. Food and Drug Administration has approved Myriad’s BRACAnalysis® CDx test for use as a companion diagnostic to identify patients with germline BRCA-mutated HER2 negative, high-risk early-stage breast cancer who may benefit from Lynparza®.

AstraZeneca and Merck, known as MSD outside the United States and Canada, announced that LYNPARZA has been approved by the U.S. Food and Drug Administration for the adjuvant treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated, human epidermal growth factor receptor 2 -negative high-risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy.

AstraZeneca and Merck & Co., Inc., known as MSD outside the US and Canada, announced LYNPARZA® has been approved in the US for the adjuvant treatment of patients with germline BRCA-mutated HER2-negative high-risk early breast cancer who have already been treated with chemotherapy either before or after surgery.

Biogen Inc. announced the company will present new Alzheimer’s disease research, as well as data for ADUHELM® injection 100 mg/mL for intravenous use, at the upcoming International Conference on Alzheimer’s and Parkinson’s Diseases, taking place March 15-20 in Barcelona, Spain and virtually.